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ABSTRACT: Chinese hamster ovary (CHO) cells are the preferred
production host for many therapeutic proteins. The production of
heterologous proteins in CHO cells imposes a burden on the host
cell metabolism and impact cellular physiology on a global scale. In
this work, a multi-omics approach was applied to study the
production of erythropoietin (EPO) in a panel of CHO-K1 cells
under growth-limited and unlimited conditions in batch and
chemostat cultures. Physiological characterization of the EPO-
producing cells included global transcriptome analysis, targeted
metabolome analysis, including intracellular pools of glycolytic
intermediates, NAD(P)H/NAD(P)þ, adenine nucleotide phosphates
(ANP), and extracellular concentrations of sugars, organic acids,
and amino acids. Potential impact of EPO expression on the protein
secretory pathway was assessed at multiple stages using
quantitative PCR (qPCR), reverse transcription PCR (qRT-PCR),
Western blots (WB), and global gene expression analysis to assess
EPO gene copy numbers, EPO gene expression, intracellular EPO
retention, and differentially expressed genes functionally related to
secretory protein processing, respectively. We found no evidence
supporting the existence of production bottlenecks in energy
metabolism (i.e., glycolytic metabolites, NAD(P)H/NAD(P)þ and
ANPs) in batch culture or in the secretory protein production
pathway (i.e., gene dosage, transcription and post-translational
processing of EPO) in chemostat culture at speciﬁc productivities
up to 5 pg/cell/day. Time-course analysis of high- and low-
producing clones in chemostat culture revealed rapid adaptation of
transcription levels of amino acid catabolic genes in favor of EPO
production within nine generations. Interestingly, the adaptation
was followed by an increase in speciﬁc EPO productivity.
Biotechnol. Bioeng. 2015;112: 2373–2387.
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Introduction
Most biopharmaceutical products like monoclonal antibodies,
hormones, and blood-related proteins are produced in Chinese
hamster ovary (CHO) cells (Walsh, 2014). Studies of CHO cells have
yielded a basic understanding of mammalian cell biology and
driven the development of mammalian cell factories for production
of structurally advanced pharmaceutical glycoproteins (Jayapal and
Wlaschin, 2007). For example, numerous studies have focused on
resolving bottlenecks in the protein production and secretory
pathway (i.e., transcription, translation, protein translocation,
-folding, -modiﬁcation and -secretion), which limit the cell-speciﬁc
protein productivity (Kim et al., 2012). Often the production
bottleneck is reported to be independent of the heterologous target
protein, indicating a general limitation of the secretory protein
processing capacity (Josse et al., 2012), while in some cases the
bottleneck is linked to the synthesis of a speciﬁc post-translational
protein modiﬁcation (Pybus et al., 2013).
In brief, protein production bottlenecks in CHO cells have been
reported at the level of transgene expression (Jiang et al., 2006; Lee
et al., 2009a; Mason et al., 2012) and stability of mRNA transcripts
(Hung et al., 2010). Numerous studies report a non-linear
correlation between mRNA copy numbers and speciﬁc protein
secretion, indicating limitations of either mRNA translation or post-
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translational processes (Chusainow et al., 2009; Lattenmayer and
Loeschel, 2007; Lattenmayer et al., 2007; Mead et al., 2009;
O’Callaghan et al., 2010; Reisinger et al., 2008). One study suggests
that the translocation of mRNA to the endoplasmatic reticulum
(ER) is limiting protein production in CHO cells (Kang et al., 2014).
Other studies have reported bottlenecks in protein folding capacity
for speciﬁc proteins (Borth et al., 2005; Chung et al., 2004; Hwang
et al., 2003; Lee et al., 2009b; Mohan and Lee, 2010). Furthermore,
some studies have found bottlenecks within vesicular transport of
proteins from ER to the Golgi apparatus and within exocytotic
transport from the trans-Golgi cisternae to the plasma membrane
(Peng and Fussenegger, 2009; Peng et al., 2011). Finally, for speciﬁc
glycoproteins, evidence suggest bottlenecks in the processing of N-
linked glycan structures (Bolt et al., 2008). In general, all major
steps (i.e., transcription, translation, protein translocation, protein
folding, protein glycosylation, and inter-organelle protein trans-
port) have been argued to be a bottleneck. In many cases, it is
possible that the cultivation method is confounding the analysis, as
one could expect that different cultivation modes (batch, fed-batch,
continuous, various forms of nutrient starvation) will have varying
requirements for native protein production, and thus inﬂuence the
metabolic load on the cell.
Cultivation of recombinant cells is performed in different ways,
depending on the goal of the experiment. In batch cultivation, all
nutrients are supplied initially in excess, allowing growth at
maximum speciﬁc rate with maximum speciﬁc nutrient uptake and
maximum production of native proteins. In an industrial context,
the batch process is of limited use for protein production, since
growth and productivity rapidly becomes limited by nutrient
availability and by-product inhibition. As an alternative process,
where growth, by-product accumulation and nutrient consumption
can be controlled, continuous cultures are operated with a constant
in-ﬂow of freshmedium, while spent medium, biomass and product
is removed at an equal rate. A popular continuous cultivation
format for physiological characterization of cells is the chemostat
(Bull, 2010), which is operated at a constant dilution rate (i.e., rate
of medium ﬂow per culture volume), thus ensuring a constant
physiochemical environment in the bioreactor. This feature enables
the study of effects of single parameters on the cell physiology.
Moreover, the restricted in-ﬂow of freshmedium allows tight control
of the growth rate of cultivated cells as availability of nutrients
becomes limiting in the culture. The operation at a ﬁxed dilution
rate thus enables the normalization of growth rates between parallel
cultures, which has been shown to be a prerequisite for global
transcriptional proﬁling as the expression level of many genes is
affected by the speciﬁc growth rate (Regenberg et al., 2006).
Chemostat cultures have been used extensively as a powerful tool for
the study of, for example, metabolism, protein production, genetic
stability, and long-term metabolic adaptation of micro-organisms
(comprehensively reviewed by Bull, 2010). However, so far only a
few studies have described the physiological characterization of
CHO cells in chemostat culture (Hayter et al., 1992, 1993; Lee et al.,
1998; Nyberg et al., 1999).
The ‘omics technologies (e.g., genomics, transcriptomics,
proteomics, metabolomics, glycomics and ﬂuxomics) provide
systems-level data on the intracellular state of a biological system
crucial to elucidate the molecular basis of CHO cell physiology
(reviewed by Kildegaard et al., 2013). Comparative analysis of
‘omics data gathered under speciﬁc physiological conditions has
revealed differentially regulated molecular mechanisms responsible
for desirable phenotypes in isogenic clone populations and guided
the design of improved cell factories (Chong et al., 2010; Sengupta
et al., 2011; Smales et al., 2004; Yee et al., 2009).
The metabolic burden imposed by heterologous protein
production in mammalian cells is still not well characterized and
thus may offer opportunities for further improvement of protein
productivity. A recent study by Niklas et al. (2013) comparing
human cells expressing a1-antitrypsin found increased anabolic
demand for RNA and lipids in protein producers and argued that
such a phenotype could be caused by increased transcriptional load
and expanded ER associated with secretory protein production. By
simulating the theoretical metabolite demand using a network
model, they linked the metabolic changes in protein producing cells
to increased C1-unit, nucleotide and lipid metabolism, which led to
speciﬁc adaptations in the amino acid metabolism and increased
secretion of glycine and glutamate. The authors concluded that C1
and lipid metabolism seem important targets for improvement of
protein production in mammalian cells.
The glycoprotein hormone erythropoietin (EPO) is a commonly
used model protein in development of CHO-based bioprocesses
(Choi et al., 2007; Sung et al., 2004; Surabattula et al., 2011; Yoon
et al., 2005) and metabolic engineering of CHO cells for improved
protein production (Kim et al., 2004, 2011). The typical EPO
expression levels from clones with no gene ampliﬁcation are
reported in the range of 1–10 pg/cell/day (Kim and Lee, 2009; Yoon
et al., 2003; Zhou et al., 2010), which is substantially lower than, for
example, antibody production processes.
The aim of the current study was to discover bottlenecks in EPO
production in CHO cells and characterize the burden of
heterologous protein production under growth dependent and
independent conditions. For this, a panel of stably EPO expressing
CHO-K1 clones spanning a 25-fold productivity range was
established and characterized in batch and chemostat cultures.
We employed a multi-omic physiological characterization including
NMR-based metabolic footprinting (exo-metabolome) of sugars,
organic acids and amino acids, LC-MS based metabolite ﬁnger-
printing (endo-metabolome) of glycolytic intermediates, NAD(P)H/
NAD(P)þ and ANPs. Quantitative PCR (qPCR), quantitative reverse
transcription PCR (qRT-PCR), Western blots (WB), and affymetrix
CHOmicroarrays were used to assess EPO gene copy numbers, EPO
gene expression, intracellular protein levels and genome-wide gene
expression analysis of differentially expressed genes functionally
related to secretory protein processing, respectively.
Materials and Methods
Cell Lines and Media
The EPO-expressing cell lines were developed from the ATCC
(Manassas, Virginia) CHO-K1 line cat no. CCL-61. Prior to cell line
development the parental cell line was adapted for suspension and
serum-free culture in a complex animal-component free Novo
Nordisk proprietary medium supplemented with 4mM L-glutamine
(Thermo Scientiﬁc, Waltham, MA). During development of EPO-
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expressing cell lines the media were supplemented with 2.5 mL anti
clumping agent (Invitrogen, Carlsbad, CA) per 1 L medium and
penicillin–streptomycin mix (Invitrogen) in concentrations of
100 U/mL of penicillin and 100mg/mL streptomycin. 600mg/mL
Geneticin/G418 (Invitrogen) was applied as selection pressure 1 day
after transfection and throughout the cell line generation process.
Primers
Primers for uracil-speciﬁc excision reagent (USER) cloning
procedure (Table I) were designed according to the USER cloning
design scheme in (Lund et al., 2014) and purchased from Integrated
DNA Technologies (Leuven, Belgium). Primers for speciﬁc
ampliﬁcation of target sequences in hEPO, b-actin (Actb) and
glyceraldehyde-3-phosphate dehydrogenase (Gapdh; Table I) were
designed using the online quantitative PCR primer design tool from
Roche (Basel, Switzerland), which is based on the Primer3 software
(Untergasser et al., 2012) and gene sequences were retrieved from
www.chogenome.org (Hammond et al., 2012).
Chemicals for Analysis of Intercellular Metabolites
Isotope-labeled standards were purchased from Silantes Gmbh
(M€unchen, Germany). All other standards of metabolites were
obtained from Sigma–Aldrich (St. Louis, MO), except for acetyl
coenzyme A that was produced by Santa Cruz Biotechnology
(Dallas, TX). High purity solvents and reagents were used in order
to reduce the background noise from impurities as much as
possible. The solvents acetonitrile and methanol used for extraction
were HPLC grade from Sigma–Aldrich while the methanol used for
chromatography was LC-MS grade from Fluka. All water was milli-
Q puriﬁed. The ion pair reagent tributylamine (TBA; HPCL grade)
was from Sigma–Aldrich, while the acetic acid (LC-MS grade) was
from Fluka.
Plasmid Construction
Avector plasmid pEPO-NEORwas assembled using the USER based
FAST-mediated vector assembly procedure as previously described
(Lund et al., 2014). Neomycin resistance was included in the
construct as selection marker. The human erythropoietin (EPO)
gene (Powell and Berkner, 1986) in the plasmid construct was
codon-optimized for CHO and synthesized from Geneart (Regens-
burg, Germany). The mammalian expression vector pU0002
(Hansen et al., 2011) harboring an Escherichia coli origin of
replication element and an ampicillin resistance gene was used as
plasmid backbone. The EPO gene was under control of the human
cytomegalovirus (CMV) promoter and ﬂanked by the bovine
growth hormone polyadenylation signal (BGHpA), while the NEOR
gene was regulated by the simian vacuolating virus 40 (SV40)
promoter and polyadenylation signal (SV40pA). USER elements
harboring promoter regions, polyadenylation signals, the NEOR
gene, and the protein backbone were produced exploiting PCR
primers and protocols from (Lund et al., 2014). Analogously, a
USER element with EPO was prepared using the uracil-containing
primers found in Table I. The NEOR gene was assembled with its
promoter and polyadenylation signal in one USER cloning event
exploiting the USER enzyme mix (New England Biolabs) and the
competent E. coli DH5a strain (Invitrogen, Carlsbad, CA) as
described in details in (Lund et al., 2014). Subsequently, the formed
selection marker element was ampliﬁed by PCR and used in a
second USER cloning procedure for generation of the vector
plasmid pEPO-NEOR. Plasmid sequence was veriﬁed by sequencing
(Star SEQ, Mainz, Germany).
Generation of EPO-Expressing Cell Lines
Transfection of the parental CHO-K1 cell line with the plasmid
vector pEPO-NEOR was performed by electroporation in a BioRad
GenePulser Xcell set to deliver a single pulse of 900mF at 300 Vand
inﬁnity resistance in a 4mm cuvette. As positive control a subset of
cells were transfected with a mammalian expression vector with the
gene for enhanced green ﬂuorescent protein (eGFP) and neomycin
resistance. The control transfection was used to estimate trans-
fection efﬁciency, follow cell death, clone expansion, and transgene
expression. Prior to each transfection 40mg of plasmid DNA was
added directly to the cuvette containing 107 cells in growthmedium.
Twenty-four hours after transfection G418 selection pressure was
added and the transfected cells were split into two. Single clones
were isolated from one half of the transfected cells in a limiting
dilution experiment with twenty 96-well plates containing either
500 or 1,000 transfected cells/well. During 2 weeks of cultivation
one 96-well plate was exposed to microscope inspection daily to
observe initial cell death and stable clones expanding. From the
untouched 96-well plates circular monoclonal cultures were
screened for EPO production using a dot blot procedure followed
by WB and enzyme-linked immunosorbent assay (ELISA; see
below) and expanded further.
Table I. List of primers and corresponding sequences used for quantitation of gene copy numbers and gene expression levels.
Primer name Target gene Purpose Primer sequence 50–30
EPO-Fwd hEPO Copy number determination AGAGGCCGAGAACATCACCA
EPO-Rev hEPO Copy number determination CCCACTTCCATCCGCTTA
GAPDH-Fwd Gapdh Copy number determination AGCTTGTCATCAACGGGAAG
GAPDH-Rev Gapdh Copy number determination ATCACCCCATTTGATGTT
ActB-Fwd Actb Copy number determination CCAGCACCATGAAGATCAAG
ActB-Rev Actb Copy number determination TGCTTGCTGATCCACATCTC
EPO (CHO optimized)-Fwd hEPO Plasmid construction AGTGCGAUATGGGCGTGCACGAGTGTC
EPO (CHO optimized)-Rev hEPO Plasmid construction AGACTGTGUTAATCTATCGCCGGTCCGGC
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The second half of the transfected cells were maintained as a
polyclonal shake ﬂask culture for 3 weeks. For the ﬁrst 2 weeks the
culture volume was gradually decreased in each passage to maintain
a viable cell density of 0.3 106 cells/mL. Single clones were
isolated from the polyclonal culture by limiting dilution into
384-well plates and robot-assisted single clone selection in a Cello
system (TAP Biosystems, Royston, UK). The cells were cultivated
and photos were taken for 13 days with medium change every
6 days. Single clone cultures were screening for EPO production and
scaled up to 30mL shake ﬂask cultures.
Screening Cell Lines for EPO Production
Isolated monoclonal cell lines were screened for EPO production
usingWB and selected clonal cultures were up-scaled and evaluated
further using the Quantikine IVD ELISA kit (R&D Systems,
Minneapolis, MN) following the manufacturer’s protocol.
The Invitrogen NuPAGE system was used for WB. Samples of
culture supernatant were drawn and centrifuged at 15,000g for 1min
and treated following the NuPage guidelines for preparation of
reduced samples and peptide N-glycosidase treated samples using
PNGases F (NewEngland Biolabs, Ipswich,MA). Sampleswere run at
12% NuPAGE Novex Bis–Tris mini gels with MOPS running buffer in
an Xcell SureLock mini cell at 200 V (constant) for 45min with
MagicMarkTM XP Western protein standard (Invitrogen) and Full-
range rainbow molecular weight marker (GE Healthcare). Gel
separated proteins were transferred by an Invitrogen iBlot device to a
nitrocellulose membrane with 0.45mm pore size (Invitrogen). 2.0%
TBS–T, was used as blocking buffer and for washing steps 0.5%
TBS–Twas employed. The membrane was incubated with 1mg/mL
polyclonal rabbit anti-EPO antibody (AbCam, Cambridge, UK) in
10mL 0.5% TBS–T at room temperature with gentle shaking at
45 rpm for 45min. Following three washing steps with 0.5% TBS–T
the membrane was incubated with 0.2mg/mL IRDye 680 goat anti-
rabbit (Li-Cor Biosciences) ﬂuorescent labeled secondary antibody in
0.5% TBS–T for 45min with shaking at 45 rpm. The membrane was
analyzed in a Li-Cor Odyssey infrared imaging system. Supernatant
from eGFP clones served as negative control.
Cell Culture
Cell culture was performed in vented Erlenmeyer shake ﬂasks
(Corning, NY) in a shaking incubator operated at 36.5C, 5% CO2
and 140 rpm. Cells were cultured in repeated batch cultivation
during the development of EPO-expressing cell lines. The cells were
passaged twice a week and the viable cell density was adjusted to
0.3 106 cells/mL.
Pre-cultures were initiated from frozen cells and cultivated as
above, but without selection pressure. The pre-cultures were
passaged every other day to ensure growth at maximum speciﬁc
growth rate.
Bioreactor Cultivation and Analysis
Parental and recombinant CHO-K1 cells were cultivated in 1.5 L
bioreactors (Eppendorf DASGIP multi-fermentor system, J€ulich,
Germany) with a working volume of 1 L. Temperature was
maintained at 36.5C with an agitation rate of 200 rpm using two
three-way segmented impellers. Dissolved oxygen was maintained
at 50% of air saturation using air, O2 and CO2 operated at a constant
ﬂow rate of 0.6 L/h. Culture pH was maintained at 7.15 with a
deadband of 0.25 using intermittent CO2 addition to the gas mix
and 2M sodium carbonate. Culture pH and pO2 was measured on-
line and calibrated to an ofﬂine reference RAPIDpoint 500 blood gas
analyzer (Siemens Healthcare Diagnostics, Erlangen, Germany)
subsequent to inoculation. Cell number, viability, cell size and
aggregation was measured using a CedeX HiRes (Roche),
extracellular concentrations of glucose, lactate, glutamine, gluta-
mate, and ammonium was measured with a Bioproﬁle 100PLUS
(Nova Medical, Waltham, MA). Supernatant samples for extrac-
ellular EPO quantitation were stored at80C until HPLC analysis.
Batch cultures were seeded with 0.3 106 cells/mL and samples
were drawn on a daily basis and analyzed for cell density, viability,
cell size, and aggregation rate. Extracted culture supernatants were
analyzed for glucose, lactate, glutamine, glutamate, ammonium,
EPO, pH, pO2, and pCO2. Genomic DNAwas extracted after 48 h and
analyzed for EPO gene copy numbers by quantitative PCR. The
culture was terminated after 160 h.
Chemostat cultures were seeded with 0.3 106 cells/mL and
chemostat cultivation mode was initiated 72 h subsequent to
inoculation with a constant dilution rate of 0.3 volumes/day. The
cultures were sampled daily and analyzed for cell density, viability,
cell size, and aggregation rate. The supernatant was analyzed for
glucose, lactate, glutamine, glutamate, ammonium, EPO, pH, pO2,
and pCO2. Samples for metabolic footprinting were analyzed for
amino acids, sugars, and organic acids by quantitative NMR
analysis (Spinnovation Biologics, Nijmegen, Netherlands). Genomic
DNA and RNA was extracted and analyzed for EPO gene copy
number and EPO gene expression level by qPCR and qRT-PCR,
respectively. Selected cultures were subjected to microarray based
gene expression analysis.
HPLC Quantitation of Erythropoietin
EPO from thawed supernatant samples was quantiﬁed by RP-HPLC
on an Agilent 1200 using an XBridge C8 4.6 150mm2 (3.5mm)
column (waters), operated at 42C and a ﬂow rate of 1 mL/min.
Buffer A was composed of 0.1% TFA in milliQ water and buffer B
was composed of 0.07% TFA in acetonitrile. The elution gradient
consisted of 30–70% buffer B over 16min. Protein detection was
performed by UV light absorption at 214 nm and EPO concen-
trationwas determined using human erythropoietin (Cell Signaling,
Danvers, MA) as standard.
Preparation of DNA, RNA, and cDNA
Genomic DNA (gDNA) was isolated from pellets of 3 106 CHO
cells using a DNAeasy blood and tissue genomic DNA puriﬁcation
kit (Qiagen, Hilden, Germany) following the manufacturers
instructions. DNA concentration and purity was determined using
a Nanodrop 8000 (Thermo Scientiﬁc, Wilmington, DE). Samples
with A260/280 ratios 2 were considered to be of sufﬁcient purity.
For total RNA isolation, 3mL culture sample was extracted and
centrifuged at 900g for 5 min. The supernatant was discarded and
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the cell pellet was homogenized in 2mLTrizol reagent (Invitrogen)
and stored at 80C. Total RNA was extracted using an RNA plus
mini kit (Qiagen) according to the manufacturer’s instructions
including column-based digestion of DNA. Total RNA quantity was
determined spectrophotometrically using a Nanodrop 8000
(Thermo Scientiﬁc) and RNA sample integrity was determined
using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA)
ensuring RIN values above 9.0.
cDNAwas generated from total RNAusing a High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster city, CA)
according to the manufacturers instructions.
Determination of Relative hEPO Gene Copy Numbers and
mRNA Levels
Relative EPO transgene copy numbers and mRNA levels were
determined using real-time quantitative PCR on gDNA and mRNA,
respectively. Primer pairs were tested for speciﬁcity and
ampliﬁcation efﬁciency. Primer dimerization and speciﬁcity was
investigated using melting curve analysis, which revealed a single
thermal transition conﬁrming that the primers were speciﬁc for the
target genes and indicating absence of primer dimerization.
Standard curves were generated from serial dilutions of pooled
gDNA in triplicates and ampliﬁcation efﬁciencies close to 100%
were achieved for all primer pairs. Primers targeting the commonly
used reference genes Gapdh and Actb were screened for
ampliﬁcation efﬁciency and Gapdh was selected as reference
gene as the primers produced ampliﬁcation efﬁciencies closer to
100%. Quantitative PCR was performed using a QuantiFast SYBR
Green PCR Kit (Qiagen) containing the ﬂuorescent dye SYBR green I
and ROX as ﬂuorescent reporter. Quantiﬁcation of relative EPO gene
dosage and expression level was carried out in 384-well plates in a
7900HT FAST Real-Time PCR System (Applied Biosystems) with a
reaction volume of 10mL. All PCR reactions were run in triplicates.
The assay was executed with the following thermal proﬁle: 10min
heat activation of the polymerase at 95C followed by 40
ampliﬁcation cycles consisting of DNA dissociation at 95C for
5 s and primer annealing at 60C for 20 s. The dissociation stage
consisted of a linear temperature ramp from 60C to 95C over the
course of 10min. The CT values were computed using the AutoCT
algorithm found in the software package SDS 2.4 (Applied
Biosystems). For calculation of gene copy numbers cells were
assumed to be diploid.
Transcriptomics Sample Preparation and Data Analysis
Chemostat cultivations of three clones (clones 1, 4, and 7) were
carried out in two parallel cultures (biological replicates) and
samples for RNA isolation were taken during the steady-state phase
of each culture, as determined by constant concentrations of
medium components (amino acids and sugars). RNA samples were
isolated from the culture as described above. RNA sample integrity
was determined using Agilent 2100 Bioanalyzer and RNA 6000
Nano LabChip kit (Agilent), ensuring RIN values above 9.0, and
total RNA quantity was determined with a NanoDrop 3300 UV–Vis
spectrophotometer (Thermo Scientiﬁc, Rockford, IL). Using the
GeneChip Hybridization, Wash and Stain Kit, the probe preparation
and hybridization to affymetrix CHO gene 2.0 ST arrays were
performed according to manufacturer’s instructions (Affymetrix
GeneChip Expression Analysis). Washing and staining of arrays
were performed using the GeneChip Fluidics Station 450 and
scanning with the Affymetrix GeneArray 3000 7G Scanner
(Affymetrix, Santa Clara, CA). The Affymetrix GeneChip Command
Console Software (AGCC) was used to generate CEL ﬁles of the
scanned arrays.
Differential gene expression analysis was performed using the
transcriptome analysis console (TAC) 2.0 (Affymetrix) software
package using one-way ANOVA, P values were corrected for
multiple comparisons by Benjamini and Hochberg False Discovery
Rate (FDR). Transcripts with a FDR P value<0.05 were considered
statistically signiﬁcant.
Western Blot Analysis of Intracellular EPO Retention
Intracellular EPO retention was examined using SDS–PAGE in
conjunction with WB analysis. Intracellular proteins were extracted
from pellets of 5 106 cells in mid-exponential phase using 1mL
Mammalian Protein Extraction Reagent with completeTM protease
inhibitor cocktail added (Thermo Scientiﬁc). The mixture was left
to react for 10min with gentle shaking and cell debris were removed
by centrifugation at 14,000g for 15min. For electrophoresis, 28mL
total protein sample was denatured with 4mL NuPage Sample
Reducing Agent (Invitrogen) and 8mL NuPage LDS Sample Buffer
(Invitrogen) at 80C for 5min and size fractionated on a 12%
NuPAGE Novex Bis–Tris mini gel with MOPS running buffer. Gel
separated proteins were transferred to a 0.45mm pore size
nitrocellulose membrane using an iBlot (Invitrogen), mouse anti-
EPO (R&D Systems) was used as primary antibody and a
ﬂuorescent labeled donkey anti-mouse antibody (Licor) was used as
secondary antibody. The ﬂuorescence was quantiﬁed using an
Odyssey CLx (Licor) with human erythropoietin (Cell Signaling) as
positive control.
Quenching and Extraction of Intracellular Metabolites
For analysis of intracellular metabolite pools, 107 cells were
extracted from mid-exponential batch cultures and immediately
quenched with four sample volumes 0C 0.9% w/v NaCl on ice
(inspired by Dietmair et al., 2010). The cooled cell suspension was
immediately spun down at 1,000g for 1 min at 0C and the
supernatant discarded. One milliliter of 79C methanol was
added to the cell pellet followed by addition of an internal standard
mixture containing 10mg/mL of [U-13C] ATP and [U-13N] AMP and
ﬂash freezing in liquid nitrogen (inspired by Sellick et al., 2010).
Samples were stored at 80C before thawing on ice and two
successive extractions were performed with 1mL 50% v/v
acetonitrile in water (inspired by Dietmair et al., 2010). The
extraction procedure included addition of solvent solution,
resuspension of cell pellet by vortexing, incubation on ice for
10min and separation of cell debris and liquid phase by
centrifugation at 4,200g for 5 min. The pooled extraction super-
natants were ﬁltered through a 0.45mm teﬂon syringe ﬁlter
Ø17mm (National Scientiﬁc, Rockwood, TN). Eight milliliter
acetonitrile was added to the ﬁltrate to facilitate water evaporation
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before drying under nitrogen atmosphere at room temperature. The
extracted metabolites were dissolved in 150mL milliQ water
containing 10mM tributylamine and 10mM acetic acid resulting in
a ﬁnal concentration of 1mg/mL of each of the internal isotope-
labeled standards. Prior to the analysis the samples were ﬁltrated
using a 0.45mm teﬂon syringe ﬁlter Ø17mm (National Scientiﬁc).
Ion-Pair Liquid Chromatography Tandem Mass
Spectrometry
All LC-MS/MS experiments were performed on an Agilent 1290
Inﬁnity LC coupled with an Agilent 6460 triple quadrupole MS
analyser equipped with electrospray ionization source. The MS was
operated in negative multiple reaction monitoring (MRM) mode.
Ten microgram/millilter single standard solutions in 10 mM
TBA and 10mM acetic acid were used to optimize the compound
speciﬁc MS and ion source parameters. The two most intense
MRM transitions for each metabolite were determined in a direct
infusion experiment using a KDS100 infusion pump with a ﬂow
rate of 9.8mL/min. Then, for each chosen MRM transition the
collision energy (CE), fragmentor and cell accelerator voltages
(CAV) were optimized by injecting 1mL of 10mg/mL single
standard solutions. When investigating the optimal compound
speciﬁc parameters for the MS/MS analysis, the following range
of voltages were tested: fragmentor voltage 90–130 V in steps of
10 V, CE 5–35 V in steps of 5 V and CAV 3 and 4 V. The MRMs
used for the analysis are given in Supplementary Materials. The
best compound speciﬁc parameters were those giving the most
intense LC-MS peak. The ion source dependent parameters were
as follows: gas temperature 300C; sheath gas temperature 400C;
nebulizer gas ﬂow rate 8 L/min; nebulizer pressure 50 psi; and
capillary voltage 4,500 V. Nitrogen was used as collision gas. The
entrance potential (DEMV) and dwell time were kept at 500 and
30ms, respectively, for all transitions.
The chromatographic separation was obtained on a Luna 2.5m
C18(2)-HST (100 2.0 mm2) HPLC column (Phenomenex, Aschaf-
fenburg, Germany) operated at 40C. Eluent Awas water containing
10mM tributylamine and 10mM acetic acid and eluent B was 90%
(v/v) methanol containing 10mM tributylamine and 10mM acetic
acid. The gradient was stepwise 0–5min, 0% B; 5–10min, 0–2% B;
10–11min, 2–9% B; 11–16min, 9% B; 16–24min, 9–50% B; 24–
28min, 50% B; 28–28.5 min, 50–100% B; 28.5–30min, 100% B;
30–30.5, 100–0% B; 30.5–36min, 0%. The ﬁnal 5.5 min were used
for equilibration of the column prior to the next run. The ﬂow rate
was 0.3 mL/min and the sample injection volume was set to 5mL.
One milligram/milliliter single standard stock solutions in water
were used to prepare 10mg/mL mixture of the compounds of
interest in eluent A. The latter mixture was used to prepare the
calibration solutions with concentrations ranging from 0.05 to
10mg/mL. Standard curves used for the quantiﬁcation were
constructed by plotting the peak area of the compounds against the
concentration. For the compounds for which internal standards
were available the calibration curves were constructed by plotting
the ratio of the peak area of labeled and unlabeled compounds
against their concentrations. A chromatogram of detected
compounds in mammalian cell extracts is supplied in Supple-
mentary Materials.
Metabolic Network Reconstruction
A draft network reconstruction of the glycolytic and amino acid
catabolic pathways in CHO cells was generated using the mouse
metabolic pathways as template. Biochemical pathway data from
mouse metabolism was retrieved from the Kyoto Encyclopedia of
Genes and Genomes database (Kanehisa and Goto, 2000; Kanehisa
et al., 2014) and homologs gene sequences in the CHO genome were
identiﬁed using the Chinese hamster genome database www.
CHOgenome.org (Hammond et al., 2012). The draft network
reconstruction was further reﬁned by careful curation of gene–
protein-reaction relationships using manual genome annotation
and literature evidence. The ﬁnalized reconstruction featured 319
proteins catalyzing 183 reactions with 188 metabolites (metabolic
map is supplied in Supplementary Materials).
Statistical Analysis
The statistical test for determination of physiological differences
between clone populations was performed using Student’s t test
with a signiﬁcance level of a¼ 0.05.
Results
Cell Line Generation and Clone Selection
Seven single cell clones were selected based on proliferation rate
and EPO expression to establish a panel of stable clones with
speciﬁc EPO productivities (qEPO) ranging from less than 0.2 to
5 pg/cell/day (determined in exponential growth phase), thus
covering a 25-fold range of productivity (Fig. 1). All EPO producing
clones and a non-transfected parental clone were adapted to the
growth medium (Q-CM105) to exclude the inﬂuence of ongoing
medium adaptation on physiological characterization. During the
adaptation phase, clones were monitored for speciﬁc growth rate,
speciﬁc glucose and glutamine uptake rates, speciﬁc lactate and
Figure 1. Specific EPO productivity. The error bars indicate standard deviation of
two biological replicates.
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ammonium secretion rates and speciﬁc EPO production rate. After
20 days in 100mL repeated batch culture, all measured parameters
had stabilized (i.e., remained within 7%). Thus, the clones were
considered fully adapted to the growth medium and a master cell
bank was established.
EPO Production Has No Effect Growth, Nutrient Uptake or
By-Product Secretion
Clones C1-7 and the parental clone were physiologically
characterized in duplicate batch cultivations in bioreactors under
nutrient excess conditions, to ensure maximum speciﬁc growth rate
(Supplementary Materials). To assess the physiological impact of
EPO production, the control was compared to the EPO producing
clones (data displayed in Table II). No signiﬁcant difference was
found in growth characteristics (i.e., speciﬁc growth rate and
biomass yield), excluding major physiological stress from EPO
production. An analysis of correlation (Supplementary Materials)
between the cell phenotypic variation displayed in Table II and qEPO
was performed to identify patterns in clone physiology that might
explain the difference in qEPO. The analysis identiﬁed no
correlations in the dataset (Table II), suggesting that an in-depth
physiological analysis was required to discover phenotypic markers
for high qEPO.
Comparison Across EPO Producing Clones Reveals No
Detrimental Effect on Glucose Metabolism
In order to assess possible metabolic impact of differential EPO
expression on energy metabolism, we performed a quantitative
characterization of intracellular metabolites related to glucose
energy and redoxmetabolism (i.e., speciﬁc glycolytic intermediates,
NAD(P)H/NAD(P)þ and ANPs). For this, triplicate batch cultures of
all EPO producing clones were sampled in parallel, during mid-
exponential growth phase and metabolite proﬁles were generated
using an extraction technique that does not differentiate between
cellular compartments, thus picturing the average concentration of
intracellular metabolites. The differences in concentrations of
adenosine phosphates and nicotinamide adenine dinucleotides did
not exhibit a marked correlation to qEPO (linear regression analysis,
R2< 0.36; Fig. 2A and C). The adenylate energy charge (AEC) ratio
represents the amount of metabolically available energy stored in
the adenine nucleotide pool (Atkinson, 1968). The catabolic and
anabolic reduction charges represent the redox state of the cell
(Andersen and von Meyenburg, 1977). The observed distributions
(Fig. 2 B, D, and E) indicate that EPO production is not limited by
insufﬁcient energy availability from adenosine phosphates or
nicotinamide adenine nucleotides (linear regression analysis,
R2< 0.36).
Furthermore, intracellular concentrations of several carbon
metabolites from glycolysis and acetyl coenzyme Awere determined
and compared between clones (Fig. 3). As observed for adenosine
phosphates and nicotinamide adenine nucleotides, the differential
qEPO was not reﬂected in metabolite concentrations indicating that
EPO production is not limited by glucose metabolism (linear
regression analysis, R2< 0.33).
Chemostat Cultivation of Three EPO Producing Clones
Show Temporal Correlations in Gene Expression and EPO
Titer
To identify the bottleneck in the protein production pathway, three
clones (C1, C4, and C7) were selected for an in-depth physiological
characterization under growth-limited conditions in duplicate
Table II. Raw data obtained in duplicate batch cultivations of EPO producing clones (C1-C7) and the parental clone (Control) in bioreactors.
Clone
mmax
(day1)
IVCD (106
cells*h/mL)
qGlc
(pmol/cell/day)
qLac
(pmol/cell/day)
qGln
(pmol/cell/day)
qGlu
(pmol/cell/day)
qNH4
(pmol/cell/day)
YLac/Glc
(mol/mol)
YNH4/Gln
(mol/mol)
qEPO
(pg/cell/day)
C1 0.97/1.00 712/639 5.88/4.52 7.08/6.91 1.10/1.07 0.20/0.17 0.94/0.73 1.20/1.53 0.86/0.69 0.18/0.17
C2 0.91/1.05 627/587 6.73/5.28 7.14/7.59 0.96/1.05 0.16/0.16 0.8 /0.64 1.06/1.44 0.84/0.61 0.36/0.21
C3 0.70/0.81 446/456 5.78/5.57 7.88/9.20 0.92/0.97 0.21/0.30 1.01/0.90 1.36/1.65 1.09/0.92 0.60/0.36
C4 0.86/0.97 544/532 4.58/4.69 6.88/7.17 1.00/1.06 0.23/0.18 0.88/0.78 1.50/1.53 0.88/0.73 0.76/0.54
C5 0.80/0.81 308/254 6.56/7.30 10.7/10.9 1.63/1.50 0.33/0.28 1.50/1.16 1.63/1.50 0.92/0.77 2.64/1.06
C6 0.89/1.00 585/579 5.86/5.18 5.96/7.42 1.05/1.00 0.20/0.21 0.87/0.72 1.02/1.43 0.82/0.71 3.05/3.39
C7 0.89/0.97 584/500 4.62/6.07 7.74/8.80 1.17/1.22 0.29/0.24 0.87/0.88 1.68/1.45 0.83/0.72 4.66/5.42
Control 0.92/0.98 528/557 4.67/4.94 7.01/7.72 1.18/1.15 0.26/0.17 0.92/0.75 1.50/1.56 0.78/0.65 —
Clone Glc/Gln consumption (mol/mol) Cell size (mm) Aggregation rate (%)
C1 5.36/4.26 13.41/13.30 29.52/15.85
C2 7.05/5.03 13.38/13.41 18.83/12.12
C3 6.27/5.73 13.05/12.90 25.85/11.97
C4 4.58/4.40 13.40/13.06 23.70/13.38
C5 4.02/4.87 16.25 / 16.01 35.04/32.18
C6 5.56/5.13 13.51/13.37 19.27/12.86
C7 3.95/4.96 13.94/13.69 20.03/8.61
Control 3.95/4.30 13.92/13.37 22.64/11.81
mmax, maximum speciﬁc growth rate; IVCD, Integral of viable cell density (biomass yield); qGlc, maximum speciﬁc glucose uptake rate; qLac, maximum speciﬁc lactate
secretion rate; qGLN, maximum speciﬁc glutamine uptake rate; qGLU, maximum speciﬁc glutamate secretion rate; qNH4, maximum speciﬁc ammonium secretion rate; YLac/Glc,
yield of lactate on glucose; YNH4/GLN, yield of ammonium on glutamine; qEPO, speciﬁc EPO productivity; Glc/GLN consumption, uptake ratio of glucose/glutamine.
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chemostat cultivations. The cultures were continued for 31 days
with a ﬁxed speciﬁc growth rate of 0.3 day1 corresponding to 15
generations at 30% of maximum growth rate. The chemostat
cultivation mode was selected to normalize for growth-related
effects on protein productivity across the three clones, thus
unveiling physiological variation in protein production efﬁciency
regardless of maximum growth capacity. The assumption was that
normalization of the speciﬁc growth rate lead to normalization of
metabolic ﬂuxes and therefore picture the intrinsic metabolic
efﬁciency of protein production between the clones. Samples were
Figure 2. Overview of intracellular energy and redox-related metabolites in EPO clones. A: Intracellular concentration of adenosine phosphates. B: Adenylate energy charge.
C: Intracellular concentration of phosphorylated and non-phosphorylated nicotinamide adenine dinucleotides. D: Catabolic reduction charge. E: Anabolic reduction charge. Error
bars indicate standard deviation of three biological replicates.
2380 Biotechnology and Bioengineering, Vol. 112, No. 11, November, 2015
taken daily from each chemostat culture and the secreted protein
levels, EPO gene copy numbers, mRNA levels (Fig. 4) and amount of
intracellular accumulated EPO were determined (Supplementary
Materials). The viable cell density (Fig. 4A), stabilized at
approximately 5 million cells/mL after 10 days. Analysis of spent
growth medium suggested that the cultures reached steady-state at
day 12, as concentrations of medium components (amino acids and
sugars) and metabolic by-products (lactate and ammonium) were
constant in all cultures from this time-point (Supplementary
Materials). The dynamics of EPO titers pictures three distinct
phases (Fig. 4B). In phase I (day 1–10) the EPO titers decrease as
the cells adjust to the imposed growth limitation and the steady
state. During phase II (day 10–20) the cells reach steady-state and
protein titers are relatively stable in all cultures. In phase III (day
20–31) the EPO titers increase corresponding to an increase of qEPO
by 56%, 74%, and 83% for clone 1, clone 4, and clone 7, respectively,
in phase III relative to phase II (Fig. 4E and F bars). The EPO gene
copy numbers were determined by qPCR using relative quantitation
with Gapdh as reference gene. The dynamics of EPO gene copy
numbers feature a steady increase over the course of the cultivation
(Fig. 4C). Starting with 1.5 relative EPO gene copies, the determined
gene copy numbers slowly increase toward two EPO gene copies,
suggesting a culture-average absolute EPO gene copy number of 3 at
the beginning of the cultivation and 4 in the end. The dynamics of
EPO gene expression pictured a decrease around day 12 consistent
in all cultures (Fig. 4D). The basis of the sudden decrease is
unknown, but the timing correlates with depletion of lactate in the
growthmedium. From day 20, the EPO gene expression increased in
all clones throughout the cultivation, correlating well with the
increased EPO titers in phase III.
Post-Transcriptional Protein Processing Efficiency of EPO
in the Protein Secretory Pathway Correlates With
Specific EPO Productivity Across Clones
For determination of differences in EPO transcription efﬁciency
across clones, we compared the ratios of culture-average EPO gene
expression per EPO gene, that is, the ratio of EPO mRNA to EPO
gene (Fig. 4E). It was noticed that the transcriptional efﬁciency of
clones 4 and 7 was identical throughout the experiment and that the
transcriptional efﬁciency of clone 1 was consistently 20% lower than
the other clones. To determine differences in post-transcriptional
Figure 3. Schematic representation of glycolysis and associated levels of intracellular metabolites. Quantified metabolites are indicated with black font on the pathway map
(left). The concentrations of 3-phosphoglycerate and 2-phosphoglycerate were pooled, as they could not be separated in the method. Error bars indicate standard deviation of three
biological replicates.
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processing of EPO across the clones, we compared the culture-
average ratios of EPO titer and EPO gene expression, that is, EPO
titer per EPO mRNA, thus reﬂecting the efﬁciency of protein
translation and secretory protein processing (protein folding,
-maturation and -secretion) across clones (Fig. 4F). It was noticed
that the post-transcriptional efﬁciency was signiﬁcantly higher in
clone 7 relative to clone 4 and clone 1 and corresponded well to the
observed difference in qEPO. Therefore, we investigated whether
different amounts of EPO were retained intracellular in the clones.
For this, total cellular protein extracts were separated using SDS–
Figure 4. Culture dynamics of clones 1, 4, and 7 during 31 days of continuous culture in chemostat. A: Viable cell densities. B: Extracellular EPO titres. C: Determined EPO gene
copy numbers. D: Determined EPO gene expression. E: Ratio of determined EPO mRNA transcript per EPO gene (curves) and averaged specific EPO productivity for phases I, II, and
III (bars). F: Ratio of secreted EPO per mRNA transcript (curves) and averaged specific EPO productivity for phases I, II, and III (bars). Error bars indicate standard deviation of two
biological replicates.
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PAGE and analyzed for EPO contents using WB (Supplementary
Materials). The differences in intracellular EPO levels corresponded
to the observed extracellular EPO titers (Fig. 4B) indicating that
EPO is not retained intracellular in any clones.
Global Gene Expression Analysis Indicate Adaptation of
Gene Expression Levels of Amino Acid Catabolic Genes
to Preserve Most Abundant Amino Acids in EPO
To identify differentially expressed genes functionally related to
secretory protein processing across the EPO producers we
performed a global gene expression analysis comparing the highest
and lowest EPO producers (clone 7 and clone 1, respectively) during
the steady-state phase of chemostat culture in phase II (triplicate
samples were generated from days 12, 15, and 18). The differential
gene expression analysis identiﬁed no enrichment in the gene
expression landscape of genes related to protein translocation,
protein folding, protein glycosylation or vesicular transport
(Supplementary Materials), indicating that neither of these
processes were limiting the protein productivity. Next, we
investigated whether the protein production bottleneck was
reﬂected in differential expression of metabolic genes. For this
analysis, we generated a network reconstruction of the glycolytic
pathway and the amino acid catabolic pathways, as these are the
most active catabolic pathways and thus most likely to limit energy
metabolism (the reconstructed metabolic network is displayed in
Supplementary Materials). The network reconstruction served as a
framework for meaningful interpretation of the differential gene
expression data on a pathway level. The results indicated a general
up-regulation of glycolytic genes in clone 7, suggesting a possible
increased energy demand in this clone. Interestingly, when
inspecting the differential gene expression levels of amino acid
catabolic genes, we discovered a tendency towards preservation of
the most abundant amino acids in EPO in the high producer relative
to the low producer (i.e., decreased transcription level of genes
responsible for degradation of the amino acids most frequently
found in EPO; Fig. 5). Speciﬁcally, 12 of the 13 most abundant and
non-secreted amino acids in EPO had reduced expression of
catabolic reactions in the high producer relative to the low producer
(Fig. 5B). Thus, the result indicated possible regulatory adaptation
of gene expression towards decreased amino acid catabolism
speciﬁc for the most abundant amino acids in EPO, in the high
producer relative to the low producer. It was noticed that the
observation was followed by an increase of qEPO by 56% and 83% in
clones 1 and 7, respectively (phase III, Fig. 4B).
Discussion
Comparison Across EPO Producing Clones Revealed No
Apparent Bottlenecks in the Protein Expression and
Secretory Pathway or Energy Metabolism
The secretory production of proteins in CHO cells can be
characterized as a cascade of protein modiﬁcation and quality
control steps catalyzing the post-translational processing of a
nascent polypeptide into a functionally mature protein (Hussain et
al., 2014). The overproduction of a heterologous protein increases
the trafﬁcking through the secretory pathway to the limit of the
protein processing capacity leading to productivity bottlenecks. To
increase the knowledge of the bottleneck associated with secretory
production of EPO in CHO cells, we established a panel of CHO-K1
clones spanning a 25-fold range of speciﬁc EPO productivity and
assessed the phenotypical differences at multiple stages within the
protein expression and secretion pathway.
The comparison of transcriptional efﬁciency (Fig. 4E) showed a
lower transcription rate per EPO gene in clone 1 compared to clone
4 and 7 throughout the experiment, indicating that the EPO gene
was inserted in a locus with less transcriptional activity in clone 1.
While clones 4 and 7 showed identical transcriptional efﬁciencies,
the comparison of post-transcriptional efﬁciency (Fig. 4F) revealed
that clones 1 and 4 were severely limited in EPO secretion per EPO
transcript compared to clone 7 (23% and 50% of C7 at day 15,
respectively). It was observed that the difference in post-
transcriptional efﬁciency corresponded to the difference in qEPO
indicating that the expression bottleneck was enrooted downstream
of transcription (i.e., translation, translocation, protein folding,
-glycosylation and -transport). The differential EPO expression was
not reﬂected in intracellular protein concentration as determined by
WB, as this correlated well with the difference in extracellular
protein concentration, indicating that post-translational processing
of EPO in the secretory pathway is not a bottleneck. This indication
was underlined by the fact that the global gene expression analysis
of clones 1 and 7 found no signiﬁcant (P values>0.05) difference in
expression level of single genes or expression enrichment within a
group of genes functionally related to secretory protein production
(i.e., genes involved in translocation, protein folding, -glycosylation
and -transport).
The determination of gene- and transcript levels during
prolonged chemostat cultivation led to some noteworthy observa-
tions. The slightly increasing trend of EPO gene copy numbers was
surprising. However, the effect may be explained by presence of a
sub-population of cells with different copy numbers of hEPO or
Gapdh, as previously demonstrated by Beckmann et al. (2012).
Similarly, the sudden decrease of EPO transcripts around day 12
(Fig. 4D) was surprising. The basis of the decrease was unknown,
but the timing in all ﬁve cultures correlated well with the depletion
of lactate in the growth medium and may be associated with a
metabolic shift.
It was investigated whether the differential EPO expression
across the clones was caused by a bottleneck in carbon and/or
energy metabolism. For this, intracellular metabolites were
sampled in mid-exponential growth phase as this was assumed
to picture the maximum metabolic capability of each clone.
Comparison of intracellular concentrations of adenosine phos-
phates and nicotinamide adenine dinucleotides across clones
showed no correlation to qEPO (Fig. 2). This observation indicated
that the energy metabolism was keeping up with the increased
energy requirement in the EPO producing clones, which is in
agreement with similar studies of other mammalian cell types
(Khoo et al., 2007; Niklas et al., 2013). Furthermore, the lack of
correlation between concentrations of glycolytic intermediates and
qEPO (Fig. 3) indicated that glucose metabolism was not limiting for
EPO productivity in batch culture. However, in the chemostat
culture, we observed a change in the expression landscape of
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Figure 5. Differential gene expression analysis of amino acid catabolic genes in the high and low producer. A: Gene expression landscape of genes catalyzing the degradation
or synthesis of amino acids. Circles indicate genes next to the reaction the encoded enzyme catalyzes. Gene expression values are shown as log fold-change indicating up- or down
regulated genes in clone 7 relative to clone 1. Amino acids are colored blue, redox active metabolites are colored red and metabolites from the central metabolism are colored
yellow. Reactions that do not produce or consume amino acids have been left out for simplicity. Dashed lines indicate multiple catalytic reactions.B: Frequency distribution of amino
acids in human EPO without signal peptide. Black bars correspond to amino acids, which are preserved in clone 7 relative to clone 1. Gray bars indicate amino acids, which are not
preserved. Red bars indicate amino acids that are secreted from the cells and therefore not considered in the analysis.
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metabolic genes between the two EPO producing clones. The genes
in the glycolytic pathway were generally up-regulated in the high
producing clone, possibly reﬂecting an increased energy demand
corresponding to the increased EPO productivity of this clone. That
is, the normalization of growth rates in chemostat culture
normalized the metabolic energy consumption from growth, thus
allowing the quantiﬁcation of energy requirement from heterol-
ogous protein production. Increased glycolytic ﬂux in response to
protein production during glucose-limited growth-restricted
culture has been demonstrated in the eukaryotic production host
Pichia pastoris (Heyland et al., 2010).
Heterologous Protein Production Causes Metabolic
Changes in Favor of the Produced Protein
Heterologous protein production imposes a metabolic burden on
the host cell metabolism, which causes redistribution of metabolic
precursor ﬂuxes to meet the increased anabolic demand for e.g.
nucleotides for synthesis of RNA and activated sugar precursors
associated with secretory protein production as shown by Niklas et
al. (2013). The same study demonstrated that anabolic demand for
nucleotide biosynthesis results in extracellular secretion of glycine
and glutamate. Interestingly, we found that during steady state in
chemostat culture, extracellular concentrations of glycine and
glutamate were 1.8- and 2-fold higher in C7 relative to C1,
respectively. This indicated that the secretion rates of glycine and
glutamate increased with qEPO, suggesting that the ﬁndings of
Niklas et al. (2013) in human cells expressing a1-antitrypsin are
also valid for CHO cells expressing EPO.
The use of a nutrient-limited cultivation format restricts the
possibility to increase nutrient uptake and inﬂict regulatory changes
on cell metabolism, which may lead to ﬂux-redistribution in favor of
the heterologous protein. To further increase the knowledge on the
adaptability of CHO cell metabolism, we performed a comparative
transcriptome analysis of two clones with 25-fold differential EPO
productivity in glucose-limited chemostat cultivations at D¼ 0.3
day1. Interestingly, we observed a change in the gene expression
landscape of catabolic genes between the clones. The genes in the
glycolytic pathway generally showed higher expression levels in the
high producing clone, possibly reﬂecting an increased energy
demand corresponding to the increased EPO productivity of this
clone. Furthermore, the comparison of gene expression levels in the
amino acid catabolism revealed a regulatory change around the
amino acids, which are most abundant in EPO and not secreted
from the cell. That is, the gene expression levels of enzymes
producing these amino acids were generally up-regulated and
expression levels of enzymes consuming the same amino acids were
generally down-regulated in the high producer relative to the low
producer (Fig. 5). This observation indicated a comparatively larger
degree of metabolic adaptation to EPO production in the high
producer, which may explain the larger increase of qEPO in the high
producer in phase III of chemostat culture (83% vs. 56% in high and
low producers, respectively). Based on these data, we speculate that
the amino acid metabolism in CHO cells may undergo adaptation in
favor of the produced heterologous protein during long-term
cultivation. The adaptation of gene expression levels in amino acid
metabolism in favor of heterologous protein production during
prolonged chemostat cultivation has been reported before in the
eukaryotic protein production host Saccharomyces cerevisiae
(Kazemi Seresht et al., 2013).
In conclusion, we provide evidence that EPO production up to
5 pg/cell/day is not limited by metabolism (i.e., glycolysis and
associated energy metabolites) or bottlenecks in gene dosage,
transcription and post-translational processing of EPO. Further-
more, we showed that glutamate and glycine secretion is increased
in the high producing EPO clone, relative to the low producing
clone, echoing the ﬁndings of Niklas et al. (2013) thus indicating
possible anabolic demand for nucleotides and lipids, which could
be candidate targets for medium supplementation to improve
protein productivity.
Finally, we demonstrate that heterologous protein production
can inﬂict metabolic changes in favor of the produced protein
during prolonged chemostat cultivation. The observed adaptations
of glycolysis and amino acid metabolismwere followed by increased
protein productivity in phase III (83% vs. 56% in high and low
producers, respectively), suggesting that metabolic engineering of
amino acid metabolism to reduce catabolism of amino acids present
in the target protein could improve speciﬁc protein productivity in
continuous culture. It was not possible to verify the reduced amino
acid catabolism at the metabolite level using metabolic foot
printing, thus future work should include quantiﬁcation of
intracellular levels of amino acid catabolic proteins or metabolic
ﬂux analysis to verify the suggested link between amino acid
catabolism and heterologous protein production in chemostat
culture.
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